TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03432923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzocaine 8 mg
Description: Benzocaine 8 mg, oval, white to slightly beige to yellow film coated tablet. One lozenge to be dissolved slowly in the mouth every 2 hours. Max 6 per day, max treatment 5 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, oval, white to slightly beige to yellow film coated tablet. One lozenge to be dissolved slowly in the mouth every 2 hours. Max 6 per day, max treatment 5 days.
Study: NCT03263754

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pocket Medic
Description: 10 short digital films utilising self-determination theory aiming to increase patient self-management

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Rehabilitation
Description: PR follows National Institute for Clinical Excellence guidelines delivering 14 sessions over 7 weeks utilising a multidisciplinary approach

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: PR follows National Institute for Clinical Excellence guidelines delivering 14 sessions over 7 weeks utilising a multidisciplinary approach
Study: NCT01155583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DNA methylation analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DNA methylation analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bone marrow aspiration
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bone marrow aspiration
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies
Study: NCT04730557

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss
Description: Each participant receives a calorie (kcal) prescription derived from calculations of estimated total energy expenditure (TEE) based on weight, height, sex, age, and activity level using equations developed by the Institute of Medicine \[29\]. Prescribed kcal levels are adjusted downward from the TEE to achieve a weekly weight loss of 1 to 2 pounds, generally a deficit of 500-1000 kcal/day. Weekly intervention sessions and activities will be delivered virtually using Microsoft Teams, Duke ZOOM or Duke Webex and led by Registered Dietitians.
Study: NCT00003557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dolastatin 10
Study: NCT05008289

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic transcutaneous spinal cord stimulation
Description: In the active group, non-invasive spinal cord stimulation will be applied by placing a circular magnetic coil (Magventure®️ MagPro®️ R20) on the skin, in the upper thoracic region (thoracic level T2-T3). The intensity of stimulation will represent 100% of the motor threshold, which is determined by abdominal muscle contractions, found from single pulses, gradually applied every 10 seconds until the onset of contractions. The intermittent theta burst stimulation protocol will consist of 20 stimulation trains, with an interval of 8 seconds between trains, each train will have 20 bursts, and each burst will have 3 pulses at 50 Hertz repeated at 5 Hertz. In total 1200 pulses will be applied for 3 minutes and 58 seconds.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation
Description: To create a sensation of muscle contraction and impression of active stimulation, both the placebo and active groups will be subjected to the sensory effect of transcutaneous electrical neurostimulation (TENS). The surface electrodes of TENS (model Neurodyn®️, Ibramed®️) will be placed in parallel at the height of the thoracic level T2-T3, with the following parameters: 80Hertz, 150ms, approximately at 60 miliampère.~In the placebo group, a coil will be allocated in the thoracic region T2-T3, however this coil will not be connected to the stimulation device, and another active coil will be positioned about 15cm behind, away from its field of view, to provide the idea from the sound stimulus that it is being stimulated.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation
Description: To create a sensation of muscle contraction and impression of active stimulation, both the placebo and active groups will be subjected to the sensory effect of transcutaneous electrical neurostimulation (TENS). The surface electrodes of TENS (model Neurodyn®️, Ibramed®️) will be placed in parallel at the height of the thoracic level T2-T3, with the following parameters: 80Hertz, 150ms, approximately at 60 miliampère.~In the placebo group, a coil will be allocated in the thoracic region T2-T3, however this coil will not be connected to the stimulation device, and another active coil will be positioned about 15cm behind, away from its field of view, to provide the idea from the sound stimulus that it is being stimulated.
Study: NCT02326428

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stent retriever endovascular device for thrombectomy
Description: Thrombectomy by selected stent retrievers (TREVO, Solitaire, pREset, in special cases all stent retrievers) as additional therapy in major artery occlusion in patients fulfilling criteria for and receiving intravenous thrombolysis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous thrombolysis by alteplase (Actilyse) (optional)
Description: Stroke thrombolysis with Alteplase (Boeringer-Ingelheim, ATC-code B01AD02; a fibrinolytic drug) according to conventional guidelines (0.9 mg/kg, not exceeding 90 mg, given intravenously)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis by alteplase (Actilyse) (optional)
Description: Stroke thrombolysis with Alteplase (Boeringer-Ingelheim, ATC-code B01AD02; a fibrinolytic drug) according to conventional guidelines (0.9 mg/kg, not exceeding 90 mg, given intravenously)
Study: NCT03349333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pralatrexate
Description: Pralatrexate will be administered at a dose of 30 mg/m2/week for 6 weeks followed by 1 week of rest in a 7-week cycle. Pralatrexate administration occurs once a week during week 1 through week 6 of each cycle.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12 and folic acid
Description: The eligible subjects will receive vitamin supplementation at screening phase, at least 10 days prior to pralatrexate administration on cycle 1, dose 1. Vitamin supplementation will consist of vitamin B12 1 mg intramuscular (IM) q 8-10 weeks and folic acid 1.2mg by mouth (PO) once a day (QD). Once pralatrexate is permanently discontinued, vitamin supplementation should continue at least 1 month after the last pralatrexate dose, or longer at the discretion of the investigator.
Study: NCT04568928

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OLTP/PE + FES
Description: 12 sessions OLTP/PE + FES
Study: NCT00054483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT01141283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
Study: NCT03639428

Intervention type: DRUG
Intervention: Midazolam
Description: All subjects received a sigle 0.3mg/kg midazolam dose os ADV6209

Intervention type: DRUG
Intervention: Midazolam
Description: All subjects received a sigle 0.3mg/kg midazolam dose os ADV6209

Intervention type: DRUG
Intervention: Midazolam
Description: All subjects received a sigle 0.3mg/kg midazolam dose os ADV6209
Study: NCT04547010

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy Isoflavone supplement
Description: Participants received 60 mg of soy-isoflavone supplement per day.
Study: NCT03382782

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BWLI
Description: BWLI includes group weight management classes, physical activity classes, individual sessions with a facilitator to address goals and barriers to weight loss, and weigh-ins.~A punch card system will be implemented to incentivize participation for BHL classes. Each participant from the BWLI condition will be given a punch card, each punch card contains 10 spaces of punches, and will receive a punch at the end of each class (either BHL or physical activity) they attend. No punch will be given if they are more than 15 minutes late for BHL class or more than 5 minutes late for physical activity class. Participants can earn $5 per punch for up to $250. They will be allowed to cash in for $50 Visa gift card every 10 punches. They cannot cash in for a partially filled card. They must have the 10 full punches to cash in.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BWLI & Peer Navigator
Description: Participants receive the BWLI condition and partner with a peer navigator. Peer navigators will meet individually and face-to-face with participants to address their health and weight goals (i.e. working on BWLI homework, attending health care appointments, and facilitating diet and exercise activities). A punch card system will be implemented to incentivize participation for BHL classes. Each participant from BWLI \& Peer Navigator will be given a punch card, each punch card contains 10 spaces of punches, and will receive a punch at the end of each class (either BHL or physical activity) they attend. No punch will be given if they are more than 15 minutes late for BHL class or more than 5 minutes late for physical activity class. Participants can earn $5 per punch for up to $250. They will be allowed to cash in for $50 Visa gift card every 10 punches. They cannot cash in for a partially filled card. They must have the 10 full punches to cash in.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integrated Care
Description: Participants receive integrated physical and mental health care from their usual provider.
Study: NCT03780348

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: New Method
Description: A 'new' WHZ tool will be used to assess children.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: New Method
Description: A 'new' WHZ tool will be used to assess children.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Existing Method
Description: 'Existing' WHZ tools will be used to assess children
Study: NCT02553525

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Stimulation Patterns
Description: During deep brain stimulation (DBS) electrode implantation or implanted pulse generator (IPG) replacement surgery, different stimulation patterns that are designed to suppress oscillatory neural activity at theta- or beta-frequencies will be delivered in randomized order, and the subject will be blinded to the patterns. Neural activity and/or motor symptoms (tremor and/or bradykinesia) will be measured in response to DBS. Measurements will be made during 2- to 8-minute trials, in which stimulation will be off for the first half of the trial, and on for the remaining half. Neural activity and/or motor symptoms will be measured during both the off and on phases. The total amount of time necessary for data collection will be about 45 minutes.
Study: NCT02194777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBN 4096 BS - in single rising doses
Study: NCT02553525

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Symptogenic Stimulation Patterns
Description: During deep brain stimulation (DBS) electrode implantation or implanted pulse generator (IPG) replacement surgery, different stimulation patterns that are designed to exacerbate oscillatory neural activity at theta- or beta-frequencies will be delivered in randomized order, and the subject will be blinded to the patterns. Neural activity and/or motor symptoms (tremor and/or bradykinesia) will be measured in response to DBS. Measurements will be made during 2- to 8-minute trials, in which stimulation will be off for the first half of the trial, and on for the remaining half. Neural activity and/or motor symptoms will be measured during both the off and on phases. The total amount of time necessary for data collection will be about 45 minutes.
Study: NCT01316510

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacteria infantis
Description: 1 billion organisms twice daily either through a feeding tube or by mouth for 6 weeks or until discharge

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dilute Nutramigen formula
Study: NCT01990885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-7010
Study: NCT01189968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Demcizumab
Description: The 6 subjects in the first cohort will receive demcizumab 5 mg/kg once every 3 weeks; the 6 subjects in the subsequent cohort will be treated with 10 mg/kg once every 3 weeks; and the 6 subjects in the final cohort will be treated with 15 mg/kg once every 3 weeks. A Data Safety Monitoring Board (DSMB) will review the data for the 6 subjects in each dose cohort after the last subject in that cohort has been on study for 56 days and then decide whether it is safe to escalate to the next highest dose cohort. Once the dose-escalation portion of the study has been completed, 14 additional subjects will be treated at the highest dose level that the DSMB deems as safe.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Demcizumab
Description: The 6 subjects in the first cohort will receive demcizumab 5 mg/kg once every 3 weeks; the 6 subjects in the subsequent cohort will be treated with 10 mg/kg once every 3 weeks; and the 6 subjects in the final cohort will be treated with 15 mg/kg once every 3 weeks. A Data Safety Monitoring Board (DSMB) will review the data for the 6 subjects in each dose cohort after the last subject in that cohort has been on study for 56 days and then decide whether it is safe to escalate to the next highest dose cohort. Once the dose-escalation portion of the study has been completed, 14 additional subjects will be treated at the highest dose level that the DSMB deems as safe.
Study: NCT01520740

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Emphysematous Lung Sealant
Description: 4 Subsegments treated - 2 each bilaterally

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Emphysematous Lung Sealant
Description: 4 Subsegments treated - 2 each bilaterally
Study: NCT01990885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-7010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-7010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-7010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-7010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03839264

Intervention type: DIAGNOSTIC_TEST
Intervention: Graft stenosis and thrombosis
Study: NCT01990885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03233243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin Oral Tablet
Description: Patients with 18F-NaF-positive plaques will be treated with 20 mg of rosuvastatin daily for six months, except in patients who need a 55% LDL reduction to achieve recommended targets (rosuvastatin 40 mg). A second visit (visit 2) will take place eight weeks after therapy initiation to monitor for compliance and adverse events report: therapy will be discontinued if there is an elevation of creatine kinase over five times the ULN with myalgia or alanine amino-transferase three times the ULN.
Study: NCT00428090

Intervention type: DRUG
Group type: OTHER
Intervention: Rosiglitazone
Description: XR (extended release) oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: XR (extended release) oral tablets
Study: NCT04553341

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Navigated repetitive transcranial magnetic stimulation
Description: In these patients we will apply the following protocol: after the initial nTMS mapping of the according function, patients will be stimulated on 20 consecutive days by a series of rTMS pulses. The frequencies (1-20 Hz), number of pulses (100-1,000), and stimulation intensities (50-130% resting motor threshold = rMT = individual lowest stimulation intensity that evokes positive muscle responses) will be applied in dependency of the individual patients comfort and the evoked effect. Stimulations will be applied to the eloquent brain region, which is infiltrated by the tumor.
Study: NCT01380951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telbivudine
Description: telbivudine 600mg/d 96 weeks
Study: NCT00733603

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Global Therapeutic Massages (GTM)
Description: Non-specific somatic treatment with full-body Western massage.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial Tissue Manipulation (MTM)
Description: Targeted internal and external Connective Tissue Manipulation focusing on the muscles and connective tissues of the pelvic floor, hip girdle, and abdomen.
Study: NCT03026023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combindation treatment with Grazoprevir and Elbasvir fixed dose combination tablet, with or without ribavirin
Description: HCV treatment for 12 to 16 weeks. Treatment length and addition of ribavirin based upon presence of baseline resistance associated variant in the HCV virus. Medications given concurrently.
Study: NCT02565290

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3
Description: Pregnant women should take 2 capsules of omega 3 (1g), 2 times a day, for 21 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Soy Oil
Description: Pregnant women should take 2 capsules of placebo 3 - soy oil oil (1g), 2 times a day, for 21 days.
Study: NCT01686789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha-2a

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon alpha-2a
Study: NCT02690974

Intervention type: DRUG
Group type: OTHER
Intervention: LCZ696 (sacubitril/valsartan)
Description: All patients were treated with the LCZ696 (sacubitril and valsartan) tablets
Study: NCT01091155

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ColonRing (Colorectal anastomosis)
Description: Creation of a colorectal compression anastomosis
Study: NCT00678314

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.2%
Description: 10 ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.75%
Description: 3 ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 10 ml
Study: NCT02678130

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: InterFuse T
Description: Transforaminal Lumbar Interbody fusion (TLIF)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care TLIF (Stryker AVS Unilif)
Description: Transforaminal Lumbar Interbody Fusion (TLIF)
Study: NCT05288660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1210
Description: All doses of ALXN1210 were administered by IV infusion, using programmable IV infusion pump and IV sets with in-line filters, at a fixed rate of 686 mg/hour (equivalent to 137 milliliters \[mL\]/hour), excluding interruption for safety or technical reason.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1210
Description: All doses of ALXN1210 were administered by IV infusion, using programmable IV infusion pump and IV sets with in-line filters, at a fixed rate of 686 mg/hour (equivalent to 137 milliliters \[mL\]/hour), excluding interruption for safety or technical reason.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All doses of placebo were administered by IV infusion, using programmable IV infusion pump and IV sets with in-line filters, at a fixed rate of 686 mg/hour (equivalent to 137 mL/hour), excluding interruption for safety or technical reason.
Study: NCT02723942

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T cell immunotherapy
Description: This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at GPC3 antigen.
Study: NCT05339048

Intervention type: GENETIC
Intervention: Genetic risk variants
Description: Exposure: Genetic predisposition to complex diseases.

Intervention type: OTHER
Intervention: Diet
Description: Exposure: dietary intake of unhealthy foods known to be associated with higher prevalence of respiratory and cardiovascular diseases.

Intervention type: BEHAVIORAL
Intervention: Physical activity
Description: Exposure: frequency of moderated or intense physical activity, and daily exposure to sedentary behavior.

Intervention type: OTHER
Intervention: Socio-economic conditions
Description: Exposure: socio-economic vulnerability indexes associated with higher prevalence of respiratory and cardiovascular diseases (including household conditions, accessibility to health care services, among others).
Study: NCT02348450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 40mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 5ml：0.1g

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 6ml：30mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 6ml：30mg
Study: NCT03202706

Intervention type: PROCEDURE
Intervention: Samples of adipose tissue
Description: Samples of visceral and subcutaneous adipose tissue collected during hernia surgery